Project Grant R03TR005864
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $170K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Mexico, USA
Similar Awards
- This $2,714,830 Project Grant was awarded on August 6, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant was awarded to The Johns Hopkins University to conduct research on the function of medium to large diameter sensory neurons in paclitaxel-induced pain via large-scale in vivo dorsal root ganglia (DRG) imaging. The research aims to determine...
- This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...
- This federal Project Grant award of $222,758 from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is funding research to map the functional roles of different neuron types in the dorsal root ganglia (DRG) and understand their contributions to pain perception in the brain. The primary awardee, the University of North Carolina at Chapel Hill (UNC-CH), will use innovative optogenetic and chemogenetic techniques to selectively...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas M.D. Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) associated with colorectal cancer and oxaliplatin treatment. The project aims to establish the face, construct, and predictive validity of this refined mouse...
- This federal Project Grant award of $597,999.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the neuronal populations and central sensitization mechanisms underlying mechanical allodynia (a condition where normally innocuous touch becomes painful after injury) in the dorsal horn. The research aims to identify the excitatory...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research by Function Therapeutics Inc. to investigate the use of a new class of small molecule compounds called Parmodulins for the treatment of neuropathic pain. The $499,863 award, granted on September 11, 2025, will fund research to synthesize and test various Parmodulins for their ability to modulate the...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- This $2,569,851 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate how the PD-L1/PD-1 immune checkpoint pathway controls physiological and pathological pain, as well as opioid analgesia, through neuronal, immune, and glial mechanisms. The project aims to validate the actions of PD-L1 and the checkpoint inhibitor nivolumab on neuroinflammation and...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $589,106 to support research on chemotherapy-induced peripheral neuropathy (CIPN). The objective is to elucidate how cellular senescence drives CIPN and impedes axonal repair, with a focus on identifying senescent cells in the peripheral nervous system and their secretory mechanisms that contribute to this condition. The 5-year project, commencing June 1, 2025, will...